Currently, commonly used biomarkers, including PD‐L1 expression and tumor mutation burden, may play a role in patient selection for immunotherapy in some cancers, such as lung cancer, but they have very limited significance for liver cancer. This evidence concerns the gene CD274 and liver cancer.